Journal article
Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias
P Cheshire, S Ayton, KL Bertram, H Ling, A Li, C Mclean, GM Halliday, SS O'Sullivan, T Revesz, DI Finkelstein, E Storey, DR Williams
Movement Disorders | Published : 2015
DOI: 10.1002/mds.26144
Abstract
Preclinical animal models implicate serotonin neurons in the pathophysiology of levodopa (l-dopa)-induced dyskinesias in Parkinson's disease (PD), but effective treatment remains elusive. We examined the relationship between serotonin and l-dopa-induced dyskinesias in a pathologically confirmed cohort of PD patients. We obtained brain tissue from 44 PD cases and 17 age-matched controls and assessed monoamine levels and the serotonin and dopamine transporters in the striatum, and the extent of dopaminergic and serotonergic cell preservation in the substantia nigra (SN) and the dorsal raphe nuclei (DRN), respectively. As expected, PD patients demonstrated a severe loss of all dopaminergic mark..
View full abstractGrants
Funding Acknowledgements
This work was funded by the CASS Foundation and the NIHR Queen Square Dementia Biomedical Research Unit. P. Cheshire received support from the Bethlehem Griffiths Research Foundation. G. Halliday is an NHMRC Senior Principal Research Fellow (630434).